D007155Chemicals & DrugsD27.505.696.47723390.957995Immunologic FactorsFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson30535188Dub? MP, Chan ES, Lake JE, Williams B, Kinslow J, Landay A, Coombs RW, Floris-Moore M, Ribaudo HJ, Yarasheski KEClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaA Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection. Clin Infect Dis. 2019 09 13; 69(7):1165-1172.Clin Infect Dis2019-09-13T00:00:002019A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection.true1Associate ProfessorAssociate Professor31139690Stefoski D, Balabanov R, Waheed R, Ko M, Koralnik IJ, Sierra Morales FAnnals of clinical and translational neurologyTreatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol. 2019 May; 6(5):923-931.Ann Clin Transl Neurol2019-04-08T00:00:002019Treatment of natalizumab-associated PML with filgrastim.31176355Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee LBMC neurologyOutcomes of natalizumab treatment within 3?years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. BMC Neurol. 2019 Jun 08; 19(1):116.BMC Neurol2019-06-08T00:00:002019Outcomes of natalizumab treatment within 3?years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.DermatologyOphthalmologyPaulineMerrillPauline Merrill349445Merrill, PaulineAssistant ProfessorSashaShafikhaniSasha H. Shafikhani41.87386750000000-87.67102690000000349571Shafikhani, SashaAssociate ProfessorDusanStefoskiDusan Stefoski349679Stefoski, DusanAssociate Professor6Assistant Professor5Associate Professor4ProfessorNeurological SciencesRush University, Rush Medical Collegetrue1Assistant ProfessorAssistant ProfessorKyleAmberKyle Amber350099Amber, KyleAssistant Professor33724354Patel A, Sul J, Gordon ML, Steinklein J, Sanguinetti S, Pramanik B, Purohit D, Haroutunian V, Williamson A, Koralnik I, Harel AJAMA neurologyProgressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy. JAMA Neurol. 2021 06 01; 78(6):736-740.JAMA Neurol2021-06-01T00:00:002021Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy.1.270020.018165623research area of0.8563770.055173641subject area for34907595Mahmud F, Roy R, Mohamed MF, Aboonabi A, Moric M, Ghoreishi K, Bayat M, Kuzel TM, Reiser J, Shafikhani SHFASEB journal : official publication of the Federation of American Societies for Experimental BiologyTherapeutic evaluation of immunomodulators in reducing surgical wound infection. FASEB J. 2022 01; 36(1):e22090.FASEB J2022-01-01T00:00:002022Therapeutic evaluation of immunomodulators in reducing surgical wound infection.true1ProfessorProfessorIgorKoralnikIgor J. Koralnik349837Koralnik, IgorProfessortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate ProfessorInternal Medicine, Division of Hematology, Oncology and Cell Therapy